SuperworthInovio Pharmaceuticals market cap INO
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $92.8M
- Highest close in our data
- $4.7B
- Jun 2020
Inovio Pharmaceuticals is worth $92.8M at the close on Oct 23, 2026, at $0.90 a share.
That is down 25% over the last year and down 94% over five years.
Its highest close in our data was $4.7B in Jun 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $92.8M | $55M | $147.9M | −24% |
| 2025 | $122.7M | $48.8M | $148.3M | +151% |
| 2024 | $48.8M | $48M | $324.4M | −65% |
| 2023 | $139.2M | $95.5M | $476.5M | −64% |
| 2022 | $389.2M | $345.9M | $999.3M | −63% |
| 2021 | $1B | $1B | $2.4B | −30% |
| 2020 | $1.5B | $298M | $4.7B | +349% |
| 2019 | $334M | $208M | $486.3M | −12% |
| 2018 | $381.4M | $356.6M | $510.1M | +2% |
| 2017 | $372.9M | $372.9M | $611.9M | −27% |
| 2016 | $514M | $366M | $809.9M | +6% |
| 2015 | $485.1M | $412M | $640.5M | −14% |
| 2014 | $567.1M | $481.3M | $884.2M | −4% |
| 2013 | $589.7M | $73.9M | $589.7M | +764% |
| 2012 | $68.3M | $54M | $95.8M | +25% |
| 2011 | $54.7M | $47.1M | $91.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Inovio Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| INOInovio Pharmaceuticals | $92.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Inovio Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.